Bordetella pertussis filamentous hemagglutinin enhances the immunogenicity of liposome-delivered antigen administered intranasally
- PMID: 9529111
- PMCID: PMC108118
- DOI: 10.1128/IAI.66.4.1764-1767.1998
Bordetella pertussis filamentous hemagglutinin enhances the immunogenicity of liposome-delivered antigen administered intranasally
Abstract
In an attempt to increase the immunogenicity of mucosally delivered antigens, we incorporated the Bordetella pertussis filamentous hemagglutinin (FHA) adhesin into liposomes containing the glutathione S-transferase of Schistosoma mansoni (Sm28GST) as a model antigen. Outbred mice immunized twice intranasally with liposomes containing a constant suboptimal dose of Sm28GST and increasing doses of FHA produced anti-Sm28GST antibodies in a FHA dose-dependent manner. The addition of 3 microg of FHA to the liposomes induced more than 10-fold-higher anti-Sm28GST antibody titers, compared to those induced by liposomes without FHA. The presence of FHA did not alter the nature of the humoral immune response, and the sera contained anti-Sm28GST immunoglobulin G1 (IgG1), IgG2a, and IgG2b. However, anti-Sm28GST IgA was only detected when at least 3 microg of FHA was added to the preparation. These results show a promising potential for FHA to enhance the immunogenicity of mucosally administered antigens incorporated into liposomes.
Figures


Similar articles
-
Adjuvant activity of free Bordetella pertussis filamentous haemagglutinin delivered by mucosal routes.Scand J Immunol. 2003 Nov;58(5):503-10. doi: 10.1046/j.1365-3083.2003.01336.x. Scand J Immunol. 2003. PMID: 14629622
-
Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis.Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7944-9. doi: 10.1073/pnas.93.15.7944. Proc Natl Acad Sci U S A. 1996. PMID: 8755582 Free PMC article.
-
Bordetella pertussis filamentous hemagglutinin delivered by mucosal routes enhances immunoglobulin levels in serum and mucosal fluids.FEMS Immunol Med Microbiol. 2008 Oct;54(1):129-36. doi: 10.1111/j.1574-695X.2008.00460.x. Epub 2008 Aug 1. FEMS Immunol Med Microbiol. 2008. PMID: 18680517
-
Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.Vaccine. 2003 Mar 7;21(11-12):1165-73. doi: 10.1016/s0264-410x(02)00516-9. Vaccine. 2003. PMID: 12559794
-
Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.Clin Exp Immunol. 2006 Jun;144(3):543-51. doi: 10.1111/j.1365-2249.2006.03097.x. Clin Exp Immunol. 2006. PMID: 16734625 Free PMC article.
Cited by
-
Mucosal Vaccine Development Based on Liposome Technology.J Immunol Res. 2016;2016:5482087. doi: 10.1155/2016/5482087. Epub 2016 Dec 29. J Immunol Res. 2016. PMID: 28127567 Free PMC article. Review.
-
Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.Clin Vaccine Immunol. 2014 Jul;21(7):972-81. doi: 10.1128/CVI.00134-14. Epub 2014 May 7. Clin Vaccine Immunol. 2014. PMID: 24807055 Free PMC article.
-
Schistosomiasis in the People's Republic of China: prospects and challenges for the 21st century.Clin Microbiol Rev. 2001 Apr;14(2):270-95. doi: 10.1128/CMR.14.2.270-295.2001. Clin Microbiol Rev. 2001. PMID: 11292639 Free PMC article. Review.
References
-
- Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular vaccines in Sweden—protective efficacy and adverse events. Lancet. 1988;i:955–960. . (Erratum, i:1238.) - PubMed
-
- Claassen E. Detection, localization and kinetics of immunomodulating liposomes in vivo. Res Immunol. 1992;143:235–241. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous